Sensorion Provides an Update on NOTOXIS, its Proof of Concept Phase 2a Clinical Trial of SENS-401 in Cisplatin-Induced Ototoxicity (CIO)
The trial assesses several outcome measures, including the rate and severity of ototoxicity, the change from baseline in Pure Tone Audiometry (PTA) (dB) throughout the study and the tolerance.
- The trial assesses several outcome measures, including the rate and severity of ototoxicity, the change from baseline in Pure Tone Audiometry (PTA) (dB) throughout the study and the tolerance.
- Géraldine Honnet, Chief Medical Officer of Sensorion, said: “I’m pleased with the progress in Sensorion’s POC Phase 2a clinical study of SENS-401 in the prevention of Cisplatin-Induced Ototoxicity.
- SENS-401 is also progressing in a second ongoing Phase 2a clinical study in the prevention of residual hearing loss following cochlear implantation.
- Sensorion is anticipating the end of patient recruitment early 2024 and the publication of POC Phase 2a clinical primary endpoint readout in H1 2024.